Saliva Advantage Position AboGen as enabling saliva-based cell research and diagnostics as a non-invasive alternative to blood. Target labs and biotech developers seeking patient-friendly sampling in serology and genetics. Offer licensing of validated saliva protocols or access to end-to-end saliva collection workflows to accelerate trials.

Vaccine Collaboration Leverage mRNA vaccine development capabilities and existing engagements with CanSino and Walvax as proof of rapid collaboration potential. Propose joint development programs for vaccine trials or companion diagnostics that use saliva-based sampling. Emphasize potential to reduce sample collection burden and improve participant experience in trials.

Global Trial Access Global trial access through established international partnerships can help CROs conduct multi-country studies with standardized saliva sampling. Provide saliva collection kits, processing support, and analytics services to accelerate global studies. Position as a scalable, field-friendly alternative to venous blood draws.

Licensing Opportunity Explore licensing of saliva-based platforms and validated assays to pharma and research institutions. Consider white-labeling or co-development arrangements to create recurring revenue streams. Leverage independent validators to de-risk and accelerate partner adoption.

Growth Readiness Strong funding backing and strategic partnerships suggest potential for rapid scale with key biotech players and CROs. Target organizations seeking non-invasive sampling to improve trial efficiency and patient retention. Propose pilot programs to demonstrate cost savings and data quality improvements with saliva workflows.